Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: is PTEN predictive of response?
Clin. transl. oncol. (Print)
; 19(3): 273-278, mar. 2017. ilus
Artigo
em Inglês
| IBECS
| ID: ibc-160182
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
Glioblastoma (GBM) is fatal. The standard radiotherapy and chemotherapy (temozolomide) followed by an adjuvant phase of temozolomide provide patients with, on average, a 2.5 months benefit. New treatments that can improve sensitivity to the standard treatment are urgently needed. Herein, we review the mechanisms and utility of poly (ADP-ribose) polymerase inhibitors in combination with radiation therapy as a treatment option for GBM patients and the role of phosphatase and tensin homologue mutations as a biomarker of response (AU9
RESUMEN
No disponible
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Biomarcadores
/
Biomarcadores Tumorais
/
Glioblastoma
/
PTEN Fosfo-Hidrolase
/
Quimiorradioterapia Adjuvante
Tipo de estudo:
Estudo prognóstico
/
Fatores de risco
Limite:
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2017
Tipo de documento:
Artigo
Instituição/País de afiliação:
University of NSW/Australia
/
University of Sydney/Australia
